Transform how you analyse drug development risk
With the only transparent analysis of drug development risk at the product level.
Drug makers entered 2017 fearing the worst about retaining their US pricing power. They exited the year more jubilant, since on most measures, 2017 delivered a resurgence for pharma and biotech. The picture was similar for the medical technology industry, though life got tougher for the smaller groups.
Our report offers analysis and expert commentary on M&A deals, venture financing, initial public offerings and FDA approvals in the pharma and medtech sectors during 2017.